AR080972A1 - PRODUCTION OF VIRAL COMPONENTS - Google Patents

PRODUCTION OF VIRAL COMPONENTS

Info

Publication number
AR080972A1
AR080972A1 ARP110101441A AR080972A1 AR 080972 A1 AR080972 A1 AR 080972A1 AR P110101441 A ARP110101441 A AR P110101441A AR 080972 A1 AR080972 A1 AR 080972A1
Authority
AR
Argentina
Prior art keywords
virus
cell culture
culture
incorporation
cells
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Dick Smit
Marinus Adrianus Oerlemans
Original Assignee
Abbott Biologicals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biologicals Bv filed Critical Abbott Biologicals Bv
Publication of AR080972A1 publication Critical patent/AR080972A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Uso de dicho método en la produccion de la vacuna contra la gripe. En forma adicional, provee a un proceso para evaluar si la incorporacion de un numero muy bajo de partículas de virus infecciosos por célula (MOI) de una cepa de virus pre-seleccionado a una composicion de cultivo celular para la propagacion de partículas virales conduce a un aumento de la produccion de partículas virales y/o partículas virales procesadas. Reivindicacion 1: Un método para la propagacion del virus de la gripe que comprende hemaglutinina inmunogénica (HA), en donde las células se cultivan en cultivo celular en un primer paso y en donde con posterioridad las partículas infecciosas de la gripe se agregan al cultivo celular en un segundo paso, en donde el medio de cultivo usado para el cultivo de las células se reemplaza antes de o durante el paso de incorporacion del virus por medio de cultivo con una osmolaridad de por lo menos 80% cuando se compara con la osmolaridad del medio de cultivo usado previamente para el cultivo de las células y que no tiene una cantidad significativamente más baja, con preferencia no menos de 50%, de la cantidad total de proteínas, factores de crecimiento y/o sales inorgánicas cuando se compara con el medio de cultivo usado previamente para el cultivo de las células, en donde la cantidad de células en el cultivo celular en el momento de la incorporacion del virus es por lo menos 0,5x106 células/ml, en donde dentro del lapso de 12 a 36 horas después de la incorporacion del virus la densidad de células vivas no es menor que 40% de la densidad celular en el momento de la incorporacion del virus, en donde el numero total de partículas virales infecciosas por células agregadas durante el paso de incorporacion del virus (Multiplicidad de la infeccion, MOl) es menos de 10-5.Use of this method in the production of the flu vaccine. Additionally, it provides a process to assess whether the incorporation of a very low number of infectious virus particles per cell (MOI) of a pre-selected virus strain into a cell culture composition for the propagation of viral particles leads to an increase in the production of viral particles and / or processed viral particles. Claim 1: A method for the spread of the influenza virus comprising immunogenic hemagglutinin (HA), wherein the cells are cultured in cell culture in a first step and wherein subsequently the infectious particles of the flu are added to the cell culture. in a second step, where the culture medium used for cell culture is replaced before or during the step of incorporating the virus through culture with an osmolarity of at least 80% when compared to the osmolarity of the culture medium previously used for cell culture and that does not have a significantly lower amount, preferably not less than 50%, of the total amount of protein, growth factors and / or inorganic salts when compared to the medium of culture previously used for cell culture, where the amount of cells in the cell culture at the time of incorporation of the virus is at least 0.5x10 6 cells / ml, where within 12 to 36 hours after virus incorporation the density of living cells is not less than 40% of the cell density at the time of virus incorporation, where the total number of infectious viral particles by aggregated cells during the virus incorporation step (Multiplicity of infection, MOl) is less than 10-5.

ARP110101441 2010-04-28 2011-04-27 PRODUCTION OF VIRAL COMPONENTS AR080972A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10161256 2010-04-28

Publications (1)

Publication Number Publication Date
AR080972A1 true AR080972A1 (en) 2012-05-23

Family

ID=42269600

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101441 AR080972A1 (en) 2010-04-28 2011-04-27 PRODUCTION OF VIRAL COMPONENTS

Country Status (3)

Country Link
AR (1) AR080972A1 (en)
TW (1) TW201202425A (en)
WO (1) WO2011134660A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
AU694592B2 (en) 1994-11-16 1998-07-23 St. Jude Children's Research Hospital Novel replication process
WO2006071563A2 (en) 2004-12-23 2006-07-06 Medimmune Vaccines, Inc. Non-tumorigenic mdck cell line for propagating viruses
US7883844B2 (en) 2006-05-11 2011-02-08 Juridical Foundation The Chemosero-Therapeutic Research Institute Method for propagating influenza virus
KR20140075022A (en) * 2006-09-15 2014-06-18 메디뮨 엘엘씨 Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
EP1911836A1 (en) 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Medium supplement for virus production
CN102216450B (en) * 2008-09-24 2014-05-14 米迪缪尼有限公司 Methods for cultivating cells, propagating and purifying viruses

Also Published As

Publication number Publication date
TW201202425A (en) 2012-01-16
WO2011134660A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
ES2555959T3 (en) Method of manufacturing viral vaccines in stem cell lines derived from airborne embryos in suspension
CN101668539B (en) Duck embryonic derived stem cell lines for the production of viral vaccines
ES2536745T3 (en) Methods of production of influenza vaccine compositions
AR065076A1 (en) VACCINE AGAINST PAPILOMAVIRUS
CL2016000240A1 (en) Immunogenic composition of fish reovirus (prv) comprising prv nucleic acid; polypeptide; attenuated or inactivated prv virus, use of the immunogenic composition that is used to treat conditions of prv infection in an animal.
AR094389A1 (en) USE OF iNOS INHIBITORS TO INCREASE THE VIVIC PERFORMANCE IN CROPS
EA200801221A1 (en) VIRAL VACCINES OBTAINED FROM CELLS WITH LOW LEVELS OF RESIDUAL CELL DNA
BRPI0518568A2 (en) Method for producing a replicative influenza virus particle without the use of helper virus, replicative influenza virus particle, Cell, composition, use of a composition, Method for generating immunological protection against infection of an individual with an influenza virus, , Nucleic acid
BRPI0922867B8 (en) respiratory syncytial virus (rsv) fusion glycoprotein (f), isolated nucleic acid, host cell, vaccine composition and purified micelle
ECSP066916A (en) VACCINE AGAINST ESTREPTOCOCO AGALACTIAE
NZ611531A (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
AR079710A1 (en) PROCESS FOR THE ADHERENT CELL CULTURE
CO7461133A2 (en) Parvovirus 5a pig, methods of use and vaccine
UA110505C2 (en) Immunogenic composition containing bordetella bronchiseptica
CL2013002723A1 (en) Method of production of a virus-like particle (vlp) of salmonid alphavirus (sav) in insect cells.
AR082281A1 (en) PARAPOXVIRUS VECTORS
AR094810A1 (en) PARVOVIRUS PORCINO 5B, METHODS OF USE AND VACCINE
CL2012003219A1 (en) Recombinant parapoxvirus comprising a parapoxvirus and heterologous DNA derived from a rabies virus; preparation process of said parapoxvirus; immunogenic composition; use of the composition to induce immune response against rabies virus in an animal.
AR080972A1 (en) PRODUCTION OF VIRAL COMPONENTS
CN103209707A (en) Viral vaccine and process for preparing the same
AR085800A1 (en) EQUINAL RINITIS VACCINE
Stittelaar et al. Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine
WO2023018817A8 (en) Truncated influenza neuraminidase and methods of using the same
MX341622B (en) An aqueous composition comprising a biological antigen and an acrylic acid polymer.
AR079970A1 (en) HIGH PERFORMANCE VIRUSES OF THE YELLOW FEVER VIRUS WITH INCREASED PROPAGATION IN THE CELLS

Legal Events

Date Code Title Description
FB Suspension of granting procedure